[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520566":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":7,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Centers for Medicare and Medicaid Services\u002F Coverage and Analysis Group","FED",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease","FDA approved monoclonal antibodies directed against amyloid for the treatment of AD",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"CMS CAG","CONTACT","410-786-2281","CMS_caginquiries@cms.hhs.gov",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Centers for Medicare and Medicaid Services","RECRUITING","Baltimore","Maryland","21244","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-76.61219,39.29038,{"lat":32,"lon":31},[35],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100520566","medicare-anti-a-mab-coverage-with-evidence-development-ced-study-100520566",false,"NCT06058234","Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study","Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)","Inclusion Criteria:\n\n* Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.\n\nExclusion Criteria:\n\n* none","ALL",{"count":47,"type":48},8680,"ESTIMATED","OBSERVATIONAL","The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).",[52,53],"Mild Alzheimer's Disease","Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","2023-09-21",{"date":56,"type":57},"2023-09-28","ACTUAL",{"date":59,"type":57},"2023-07-06",{"date":61,"type":48},"2029-06-30",{"name":5,"class":6},1]